ReviewFrontiers in endocrinology2026
Nesfatin-1 across human reproduction and early life: implications for infertility, pregnancy complications, and lactation.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nesfatin-1, a peptide derived from nucleobindin-2 (NUCB2), is a widely expressed neuroendocrine factor originally identified for its anorexigenic effects in the central nervous system. Beyond energy homeostasis, accumulating evidence implicates nesfatin-1 in the regulation of glucose metabolism, stress-axis activity, inflammation, and reproductive function. These properties make nesfatin-1 particularly relevant to human reproduction and early life, physiological states characterized by profound metabolic and endocrine adaptations. The objective of this review is to examine whether nesfatin-1 functions as an integrative endocrine signal linking metabolic, stress-related, and reproductive pathways across the reproductive life course. We synthesize current human evidence on nesfatin-1 in infertility, assisted reproductive technologies, pregnancy adaptations and complications, the maternal-fetal interface, lactation, and postpartum metabolic recovery. Nesfatin-1 has been detected in several biological compartments relevant to reproductive physiology, including maternal plasma, follicular fluid, amniotic fluid, cord blood, and human breast milk. Clinical studies investigating these compartments report heterogeneous findings, with nesfatin-1 levels described as increased, decreased, or unchanged across similar clinical conditions. This variability likely reflects the context-dependent regulation of nesfatin-1 by metabolic status, stress-axis activation, inflammatory signaling, and reproductive stage. In this review, we synthesize current human evidence on nesfatin-1 across the continuum of reproduction, pregnancy, early development, and lactation, and propose a framework to reconcile these inconsistent findings. We argue that nesfatin-1 should be viewed as a context-dependent endocrine integrator reflecting the interaction of metabolic, stress-related, inflammatory, and reproductive axes rather than as a unidirectional biomarker. We further highlight key methodological challenges, including assay variability, timing of sampling, and population heterogeneity, and discuss the potential of nesfatin-1 as a longitudinal or stratification biomarker in reproductive endocrinology. Finally, we outline priorities for future research to clarify its physiological role and translational relevance in human reproduction and early life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.